98%
921
2 minutes
20
Breast cancer (BC) remains one of the most prevalent and life-threatening malignancies worldwide, marked by significant heterogeneity and complex mechanisms of progression. Despite major advances in understanding its molecular and cellular basis, the processes driving tumor progression and metastasis continue to challenge effective treatment. Among the emerging research areas, extracellular vesicles (EVs) have gained considerable attention for their key role in intercellular communication and their contribution to cancer biology. In BC, tumor cell-derived EVs are implicated in multiple processes that promote disease progression, including tumor growth, remodeling of the tumor microenvironment, and facilitation of metastasis. By transferring oncogenic signals to recipient cells, EVs critically shape the metastatic niche and support the spread of cancer cells to distant organs. Recent studies highlight the diverse functions of BC-derived EVs in modulating immune responses, inducing angiogenesis, and enhancing cancer cell invasiveness. This review explores the role of BC-derived EVs in tumor progression and metastasis. We discuss their molecular composition, mechanisms of action, and impact on the tumor microenvironment, aiming to provide insights into their role in BC pathophysiology and discuss potential clinical applications. A deeper understanding of the complex interplay between EVs and cancer progression may pave the way for innovative strategies to combat BC and improve patient outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384438 | PMC |
http://dx.doi.org/10.3390/biom15081195 | DOI Listing |
J Environ Pathol Toxicol Oncol
January 2025
Department of Clinical Laboratory Medicine, Fujian Medical University, Fuzhou, China.
Invasive ductal carcinoma (IDC) is a major type of breast cancer. The utilization of inhibitors targeting histone methyltransferases introduces novel therapeutic avenues for the treatment of cancer. Immunohistochemistry, Western blot, and reverse transcription quantitative polymerase chain reaction experiments were applied to assess the levels of EHMT2 in IDC and adjacent tissues.
View Article and Find Full Text PDFJ Environ Pathol Toxicol Oncol
January 2025
Department of Gynecology, Pucheng County People's Hospital, Weinan, China.
Long non-coding RNAs (lncRNAs) are involved in the numerous types of tumors. The aim of this study is to comprehend the pathological mechanism of lncRNA CASC19 in ovarian cancer. CASC19, miR-761 and CBX2 expression in the samples was quantitatively detected by real-time quantitative polymerase chain reaction (RT-qPCR) reaction.
View Article and Find Full Text PDFJ Neurosurg Case Lessons
September 2025
Department of Neurosurgery, Kantonsspital Aarau, Switzerland.
Background: Meningioma en plaque (MEP) is a rare subtype of meningioma with a carpet-like growth pattern, often causing hyperostosis. Even rarer is the presentation of bilateral MEP posing diagnostic and therapeutic challenges. Management of MEP usually entails early complete resection.
View Article and Find Full Text PDFJ Vis Exp
August 2025
Department of Neuroscience and Pharmacology, Carver College of Medicine, University of Iowa; Department of Radiation Oncology, Holden Comprehensive Cancer Center, University of Iowa; Geminii, Inc.
Non-small cell lung cancer (NSCLC) continues to be the number one cause of cancer-related death for both women and men worldwide. More information needs to be gathered to understand the interactions between cancer cells, the immune system, the microenvironment within each tumor, and the host tissue to develop more effective treatment modalities. Reported here is a simple, repeatable method for inducing cancer within the mouse lung, allowing for the monitoring of tumor growth from early to late-stage disease.
View Article and Find Full Text PDFBr J Dermatol
September 2025
Clinical Oncology, Guy's and Thomas' NHS Foundation Trust, London, uk.
Background: Primary Cutaneous CD4+ Small Medium T Cell Lymphoproliferative Disorder (PCSM-TLPD) is a rare subtype of indolent lymphoproliferative disease. The treatment, investigations and follow-up protocol are being re-evaluated.
Objective: To use our service evaluation to understand the presentation, response rate, relapse rate, treatment variation, progression free and overall survival of our cohort.